Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Dose-Ranging Study of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

NCT04492722 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04492722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04492722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Dose-Ranging Study of AZD5718 in Participants With Proteinuric Chronic Kidney Disease
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Terminated
Start date
October 1, 2020
Completion date
September 6, 2022
Enrollment
613 (actual)
Sites
111

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease